Biotech Companies Settle Lawsuit Against Columbia Over Lucrative Licensing Deals
The companies said the settlement will let them continue to sell their drugs to treat multiple sclerosis and Gaucher disease based on a technology developed at Columbia in the 1970s.
Neither of the parties involved would provide financial details.
The lawsuit was brought by Amgen Inc., Biogen Idec Inc., Genentech Inc., Johnson & Johnson, Genzyme Corp. and Wyeth Pharmaceuticals....
To view the full article, register now.